Alnylam Pharmaceuticals Reports Q3 Operating Income of $345.798 Million
Story updates
12:04:46 PM UTC
SquawkNews
ALNYLAM PHARMACEUTICALS Q3 ADJUSTED OPERATING INCOME USD 424.916 MILLION
Related stories
Rafael Holdings Reports FY 2026 Revenue of $874K, Net Loss of $29.6M
The company’s attributable net loss narrowed from $30.5 million a year earlier, while its consolidated net loss was $28 million. Operating loss widened to $33.4 million.
M impact | EARNINGS | Oct 29, 2026, 03:45 PM UTC
Nestlé Nigeria Posts 976.53 Billion Naira Revenue, 193.88 Billion Naira PBT for Jan-Sep 2026
M impact | EARNINGS | Oct 29, 2026, 03:45 PM UTC
Islandsbanki Q3 net interest income ISK 15,800 million
M impact | EARNINGS | Oct 29, 2026, 03:45 PM UTC
Islandsbanki Reports Q3 Net Income of ISK 7,300 Million
L impact | EARNINGS | Oct 29, 2026, 03:45 PM UTC
Caterpillar Sticks to Annual Sales Forecast Amid Cost Pressures
Caterpillar maintained its annual sales forecast amid cost pressures.
L impact | EARNINGS | Oct 29, 2026, 03:44 PM UTC
Eli Lilly Shares Jump 7% as Company Raises 2026 Outlook
Eli Lilly shares surged nearly 7% on Thursday after the company raised its 2026 outlook.
M impact | EARNINGS | Oct 29, 2026, 03:44 PM UTC